The RBM11 antibody is a crucial tool for studying the RNA-binding motif protein 11 (RBM11), a member of the RNA-binding protein family involved in post-transcriptional gene regulation. RBM11 plays roles in RNA splicing, stability, and translation, with implications in cellular processes like differentiation, apoptosis, and cancer progression. It is also linked to neurological disorders, such as amyotrophic lateral sclerosis (ALS). The antibody, typically generated in rabbit or mouse hosts, enables the detection and analysis of RBM11 expression and localization via techniques like Western blotting, immunohistochemistry (IHC), immunoprecipitation (IP), and immunofluorescence (IF). Its specificity is validated using knockout (KO) controls or siRNA-mediated knockdown to minimize cross-reactivity with homologous proteins (e.g., RBM5 or RBM10). Commercially available from suppliers like Abcam, Thermo Fisher, and Sigma-Aldrich, RBM11 antibodies are widely used to explore its oncogenic roles, such as upregulated expression in prostate cancer or glioblastoma, or its interaction with splicing factors like PTBP1. Researchers also employ it to study RBM11’s involvement in neurodevelopment and neurodegeneration. Proper validation, including concentration optimization and positive/negative controls, ensures reliable results. This antibody remains pivotal in elucidating RBM11’s molecular mechanisms and therapeutic potential.